Addex Therapeutics Ltd (FRA:APE)
Germany · Delayed Price · Currency is EUR 0.0475
-0.0030 (-5.94%)
At close: Oct 23, 2025
Addex Therapeutics Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 0.06 | 0.4 | 1.61 | 1.42 | 2.92 | 3.61 | Upgrade |
Other Revenue | 0.11 | 0.01 | 0 | 0.02 | 0.24 | 0.27 | Upgrade |
| 0.17 | 0.41 | 1.62 | 1.44 | 3.15 | 3.88 | Upgrade | |
Revenue Growth (YoY) | -79.93% | -74.64% | 11.92% | -54.18% | -18.71% | 36.90% | Upgrade |
Cost of Revenue | 0.66 | 0.85 | 1.19 | 8.23 | 12.82 | 10.37 | Upgrade |
Gross Profit | -0.49 | -0.44 | 0.43 | -6.78 | -9.67 | -6.49 | Upgrade |
Selling, General & Admin | 1.91 | 2.31 | 2.67 | 3.76 | 5.84 | 5.75 | Upgrade |
Operating Expenses | 1.91 | 2.31 | 2.67 | 3.76 | 5.84 | 5.75 | Upgrade |
Operating Income | -2.41 | -2.76 | -2.24 | -10.54 | -15.51 | -12.24 | Upgrade |
Interest Expense | -0 | -0 | -0 | -0.03 | -0.06 | -0.07 | Upgrade |
Interest & Investment Income | 0 | 0.01 | 0.06 | 0.03 | 0.01 | 0.04 | Upgrade |
Earnings From Equity Investments | -3.73 | -2.18 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -0.01 | 0.02 | -0.32 | -0.26 | 0.21 | -0.58 | Upgrade |
EBT Excluding Unusual Items | -6.15 | -4.91 | -2.5 | -10.8 | -15.35 | -12.86 | Upgrade |
Pretax Income | -6.15 | -4.91 | -2.5 | -10.8 | -15.35 | -12.86 | Upgrade |
Earnings From Continuing Operations | -6.15 | -4.91 | -2.5 | -10.8 | -15.35 | -12.86 | Upgrade |
Earnings From Discontinued Operations | 0.1 | 11.97 | -8.06 | -10 | - | - | Upgrade |
Net Income | -6.05 | 7.06 | -10.56 | -20.8 | -15.35 | -12.86 | Upgrade |
Net Income to Common | -6.05 | 7.06 | -10.56 | -20.8 | -15.35 | -12.86 | Upgrade |
Shares Outstanding (Basic) | 99 | 98 | 74 | 45 | 34 | 27 | Upgrade |
Shares Outstanding (Diluted) | 99 | 98 | 74 | 45 | 34 | 27 | Upgrade |
Shares Change (YoY) | 9.98% | 32.04% | 64.45% | 32.43% | 27.88% | 0.96% | Upgrade |
EPS (Basic) | -0.06 | 0.07 | -0.14 | -0.46 | -0.45 | -0.48 | Upgrade |
EPS (Diluted) | -0.06 | 0.07 | -0.14 | -0.46 | -0.45 | -0.48 | Upgrade |
Free Cash Flow | -1.44 | -5.37 | -8 | -16.44 | -14.74 | -12.24 | Upgrade |
Free Cash Flow Per Share | -0.01 | -0.06 | -0.11 | -0.36 | -0.43 | -0.46 | Upgrade |
Gross Margin | -294.76% | -108.35% | 26.62% | - | - | -167.41% | Upgrade |
Operating Margin | -1438.85% | -671.94% | -138.70% | -729.50% | -491.74% | -315.62% | Upgrade |
Profit Margin | -3616.42% | 1720.75% | -652.75% | -1439.78% | -486.85% | -331.48% | Upgrade |
Free Cash Flow Margin | -861.98% | -1310.80% | -494.64% | -1137.59% | -467.34% | -315.52% | Upgrade |
EBITDA | -2.33 | -2.56 | -2.23 | -10.53 | -15.16 | -11.86 | Upgrade |
EBITDA Margin | - | - | -137.97% | - | - | - | Upgrade |
D&A For EBITDA | 0.08 | 0.19 | 0.01 | 0.01 | 0.35 | 0.38 | Upgrade |
EBIT | -2.41 | -2.76 | -2.24 | -10.54 | -15.51 | -12.24 | Upgrade |
EBIT Margin | - | - | -138.70% | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.